More options are always better, right? Obviously, that’s a “yes” when it comes to building our dream Tesla Model S. But big biopharma is ...

Compared to other types of financing, royalty-based deals in the biopharma world are rare. That’s because a company needs products with f...

Certain sounds signify the Fourth of July season in the U.S. – the pop and boom of fireworks, the sizzle of burgers and hot dogs on the ...

The big funding news this fortnight doesn’t come from public or private investors, it comes from taxpayers. As " The Pink Sheet ...

Was FOTF the only one to notice that anti-obesity drug maker Vivus aced its FDA advisory committee review on Feb. 22, one day...

The news from around the globe wasn’t pretty this week, as uprisings in the streets coincided with dangerous weather, spreading misery from ...